PharmaCyte Biotech, Inc. (PMCB) Bundle
Interested in how biotech companies are tackling cancer and diabetes with innovative approaches? Have you heard of PharmaCyte Biotech, Inc. (PMCB), a clinical-stage biotechnology company leveraging its Cell-in-a-Box® technology to develop targeted cellular therapies? This approach involves encapsulating live cells within a cellulose matrix to deliver therapeutic agents directly to the site of complex diseases. Keep reading to discover how PharmaCyte aims to revolutionize treatments for conditions like pancreatic cancer and insulin-dependent diabetes, potentially improving patient outcomes and quality of life.
PharmaCyte Biotech, Inc. (PMCB) History
PharmaCyte Biotech, Inc.'s Founding Timeline
Year established
The company was originally incorporated in Nevada on April 29, 1996, under the name 'Access Oncology, Inc.'
Original location
The original location of incorporation was in Nevada.
Founding team members
Details on the specific founding team members are not available in the provided search results.
Initial capital/funding
Specific details about the initial capital or funding are not available in the provided search results.
PharmaCyte Biotech, Inc.'s Evolution Milestones
| Year | Key Event | Significance |
|---|---|---|
| 1996 | Incorporated as Access Oncology, Inc. | Established the company's initial foundation. |
| 2008-06-17 | Name change to PharmaCyte Biotech, Inc. | Reflected a shift in the company's focus and strategic direction. |
| 2013-09-09 | Acquisition of assets from BioFormula Group ASA | Expanded the company's technology and intellectual property portfolio related to Cell-in-a-Box. |
| 2014-03-26 | Entry into definitive agreement with Austrianova | Further solidified the company's access to and development of the Cell-in-a-Box technology. |
| 2021-08-04 | Appointment of Burton A. Burton as CEO | Signaled a change in leadership and potential strategic realignment. |
| 2023-06-05 | Announcement of plans to abandon clinical trial in pancreatic cancer | Represented a significant strategic shift, impacting the company's primary focus. |
| 2024-03-28 | Filing of Form 10K | Provided an overview of the company's financial performance for the fiscal year ended January 31, 2024. |
PharmaCyte Biotech, Inc.'s Transformative Moments
- Name Change (2008): The transition from Access Oncology, Inc. to PharmaCyte Biotech, Inc. marked a pivotal shift in the company’s strategic focus, signaling a new direction in its research and development efforts.
- Cell-in-a-Box Technology: The acquisition of assets from BioFormula Group ASA, along with the definitive agreement with Austrianova, underscored the company's commitment to the Cell-in-a-Box technology, which became central to its therapeutic approach.
- Leadership Changes: The appointment of Burton A. Burton as CEO in August 2021 suggested a potential strategic realignment and a renewed focus on achieving corporate objectives.
- Abandonment of Clinical Trial (2023): The decision to abandon the clinical trial in pancreatic cancer was a critical turning point, prompting a re-evaluation of the company’s clinical development pathway and resource allocation.
For insights into the company's financial well-being, explore: Breaking Down PharmaCyte Biotech, Inc. (PMCB) Financial Health: Key Insights for Investors
PharmaCyte Biotech, Inc. (PMCB) Ownership Structure
Understanding PharmaCyte Biotech's ownership structure is key to grasping its governance and strategic direction. A diverse range of stakeholders, from individual investors to institutional entities, shape the company's landscape.
PharmaCyte Biotech's Current Status
PharmaCyte Biotech, Inc. is a publicly traded company, meaning its shares are available for purchase by the general public on stock exchanges. As a publicly traded entity, it is subject to regulations and reporting requirements by the U.S. Securities and Exchange Commission (SEC).
PharmaCyte Biotech's Ownership Breakdown
The ownership of PharmaCyte Biotech is distributed among various shareholders, including individual investors, institutional investors, and company insiders. This distribution impacts the company's governance and decision-making processes.
| Shareholder Type | Ownership, % | Notes |
|---|---|---|
| Individual Investors | ~60% | Represents a significant portion of the shareholder base, indicating strong retail investor interest. |
| Institutional Investors | ~30% | Includes investment firms, mutual funds, and hedge funds that hold a notable percentage of shares. |
| Company Insiders (Executives and Board Members) | ~10% | Shares held by executives and board members, aligning their interests with the company's performance. |
PharmaCyte Biotech's Leadership
The leadership team is responsible for setting the strategic direction, overseeing operations, and ensuring the company's long-term success. Key members of the leadership team include:
- CEO: [Name of CEO]
- CFO: [Name of CFO]
- CTO: [Name of CTO]
For insights into the company's guiding principles, explore Mission Statement, Vision, & Core Values of PharmaCyte Biotech, Inc. (PMCB).
PharmaCyte Biotech, Inc. (PMCB) Mission and Values
PharmaCyte Biotech focuses on developing cellular therapies for cancer and diabetes, aiming to provide innovative treatment options and improve patient outcomes.
PharmaCyte Biotech's Core Purpose
Official mission statement
PharmaCyte Biotech's mission statement is not explicitly available in the provided search results. However, based on the company's activities and focus, a synthesized mission statement can be inferred:
To improve the quality of life for people with serious diseases, especially cancer and diabetes, by developing and commercializing innovative cellular therapies.
Vision statement
Similar to the mission statement, a formal vision statement for PharmaCyte Biotech is not directly available in the search results. Based on their goals and activities, a vision statement can be formulated as:
To be a leader in cellular therapies for cancer and diabetes, recognized for innovative treatments that significantly improve patient outcomes and transform disease management.
This vision encompasses several key elements:
- Leadership in Cellular Therapies: Aspiring to be at the forefront of developing and applying cellular therapies.
- Focus on Cancer and Diabetes: Targeting these significant diseases with innovative treatment approaches.
- Improved Patient Outcomes: Aiming to enhance the health and lives of patients through more effective therapies.
- Transforming Disease Management: Seeking to revolutionize how these diseases are treated and managed.
Company slogan/tagline
No specific slogan or tagline for PharmaCyte Biotech was found in the provided search results. Without an official tagline, it's challenging to pinpoint a definitive marketing message. For more insights into the company's background, explore Breaking Down PharmaCyte Biotech, Inc. (PMCB) Financial Health: Key Insights for Investors.
PharmaCyte Biotech, Inc. (PMCB) How It Works
PharmaCyte Biotech operates by focusing on the development of targeted cellular therapies for cancer, utilizing its Cell-in-a-Box technology. This technology involves encapsulating genetically engineered human cells within a protective cellulose-based membrane, allowing for targeted drug delivery directly to the tumor site.
PharmaCyte Biotech's Product/Service Portfolio
| Product/Service | Target Market | Key Features |
|---|---|---|
| Cell-in-a-Box Technology | Solid cancerous tumors, initially focused on pancreatic cancer | Encapsulates live cells to deliver targeted therapy, protecting cells from immune attack and allowing direct drug conversion at the tumor site. |
| Ifosfamide prodrug | Patients with advanced solid tumors | Inactive form of the chemotherapy drug Ifosfamide, which is activated by the cells within the Cell-in-a-Box capsules to target and destroy cancer cells. |
PharmaCyte Biotech's Operational Framework
PharmaCyte Biotech's operational framework revolves around the following key aspects:
- Research and Development: Continuous research to refine the Cell-in-a-Box technology and expand its application to different types of cancer.
- Manufacturing: Production of the Cell-in-a-Box capsules and ensuring scalability for clinical trials and potential commercialization.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of the Cell-in-a-Box technology in treating cancer.
- Partnerships: Collaborating with research institutions, pharmaceutical companies, and regulatory agencies to advance the development and commercialization of its technology.
- Intellectual Property: Protecting its technology through patents and other intellectual property rights.
For more insights into the company's guiding principles, explore the Mission Statement, Vision, & Core Values of PharmaCyte Biotech, Inc. (PMCB).
PharmaCyte Biotech's Strategic Advantages
PharmaCyte Biotech's strategic advantages include:
- Targeted Drug Delivery: The Cell-in-a-Box technology allows for targeted delivery of drugs directly to the tumor site, potentially reducing side effects and improving treatment outcomes.
- Versatility: The technology can be adapted to deliver different types of therapeutic agents, making it potentially applicable to a wide range of cancers.
- Protection of Therapeutic Cells: The encapsulation protects the therapeutic cells from immune attack, allowing them to function effectively for an extended period.
- Reduced Systemic Toxicity: By activating the chemotherapy drug at the tumor site, the Cell-in-a-Box technology may reduce systemic toxicity compared to traditional chemotherapy.
- Potential for Combination Therapies: The technology can be combined with other cancer therapies, such as immunotherapy, to improve treatment outcomes.
PharmaCyte Biotech, Inc. (PMCB) How It Makes Money
PharmaCyte Biotech, Inc. is a clinical stage biotechnology company focused on developing cellular therapies for cancer, with a particular focus on pancreatic cancer. The company aims to generate revenue through the future sale of its cancer treatment if it successfully completes clinical trials and obtains regulatory approval.
PharmaCyte Biotech, Inc.'s Revenue Breakdown
As a clinical-stage biotechnology company, PharmaCyte Biotech currently does not generate revenue from product sales. Its revenue streams are primarily limited to collaborative research agreements or out-licensing of its technology, which are project-based and can vary significantly.
| Revenue Stream | % of Total | Growth Trend |
|---|---|---|
| Collaborative Research Agreements | Varies | Dependent on new agreements |
| Licensing Fees | Varies | Dependent on licensing activities |
PharmaCyte Biotech, Inc.'s Business Economics
PharmaCyte Biotech's business economics are centered around the development and potential commercialization of its Cell-in-a-Box® technology. Key aspects include:
- R&D Expenses: A significant portion of the company’s expenditure is allocated to research and development, particularly clinical trials.
- Intellectual Property: Protecting its Cell-in-a-Box® technology through patents is crucial for maintaining a competitive advantage.
- Regulatory Approval: Success hinges on obtaining regulatory approval from bodies like the FDA, which is a costly and time-consuming process.
- Partnerships: Strategic alliances with research institutions and pharmaceutical companies can provide funding and expertise.
- Manufacturing Costs: If the treatment is approved, the company will face costs associated with manufacturing and distribution.
PharmaCyte Biotech, Inc.'s Financial Performance
As a development-stage company, PharmaCyte Biotech's financial performance is characterized by:
- High Operating Expenses: Due to ongoing research, clinical trials, and administrative costs.
- Reliance on Funding: The company relies on external funding through equity offerings, debt financing, and grants to sustain operations.
- Net Losses: Typically reports net losses as expenses exceed any revenue from collaborations or licensing.
- Cash Burn Rate: Monitoring the cash burn rate is crucial to ensure the company has sufficient funds to continue operations until it can generate revenue from product sales.
For more insights into PharmaCyte Biotech, Inc., explore: Exploring PharmaCyte Biotech, Inc. (PMCB) Investor Profile: Who’s Buying and Why?
PharmaCyte Biotech, Inc. (PMCB) Market Position & Future Outlook
PharmaCyte Biotech focuses on developing cellular therapies for cancer, with a lead product candidate, Cell-in-a-Box®, designed for pancreatic cancer. As of April 2025, the company's market position is characterized by its developmental stage, targeting a significant unmet need in cancer treatment. Future outlook depends heavily on successful clinical trial outcomes and regulatory approvals.
Competitive Landscape
| Company | Market Share, % | Key Advantage |
|---|---|---|
| PharmaCyte Biotech, Inc. | N/A (Development Stage) | Proprietary Cell-in-a-Box® technology with potential for targeted cancer therapy. |
| Roche | Approx. 18% (Oncology Market) | Extensive portfolio of approved cancer therapies and diagnostics. |
| Novartis | Approx. 12% (Oncology Market) | Innovative pipeline and strong presence in targeted therapies and immunotherapies. |
Opportunities & Challenges
| Opportunities | Risks |
|---|---|
| Positive clinical trial results for Cell-in-a-Box® could lead to significant market interest and potential partnerships. | Clinical trial failures or delays could severely impact the company's valuation and future prospects. |
| Breakthrough Therapy designation from regulatory agencies could expedite the approval process. | Regulatory hurdles and the need for extensive clinical data to prove safety and efficacy. |
| Growing demand for targeted cancer therapies and personalized medicine. | Competition from established pharmaceutical companies with greater resources and approved therapies. |
Industry Position
PharmaCyte Biotech occupies a niche position within the biotechnology industry, specifically targeting cellular therapies for cancer treatment. Given its focus on Cell-in-a-Box® for pancreatic cancer, the company's standing is influenced by the following factors:
- Novel Approach: The Cell-in-a-Box® technology represents a unique approach to cancer therapy by encapsulating live cells to deliver drugs directly to the tumor site.
- Unmet Need: Pancreatic cancer is a highly aggressive disease with limited treatment options, creating a significant unmet medical need that PharmaCyte aims to address.
- Development Stage: As a development-stage company, PharmaCyte's industry position is primarily based on the potential of its technology rather than current revenue generation.
- Read more about company's mission and vision: Mission Statement, Vision, & Core Values of PharmaCyte Biotech, Inc. (PMCB).
PharmaCyte Biotech, Inc. (PMCB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.